67 related articles for article (PubMed ID: 27122129)
1. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
Motlló C; Ribera JM; Morgades M; Granada I; Montesinos P; Brunet S; Bergua J; Tormo M; García-Boyero R; Sarrà J; Del Potro E; Grande C; Barba P; Bernal T; Amigo ML; Grau J; Cervera J; Feliu E;
Leuk Lymphoma; 2017 Jan; 58(1):145-152. PubMed ID: 27122129
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia.
Sarkar S; Rav E; Stitzlein L; Gibson A; McCall D; Nunez C; Roth M; Ragoonanan D; Connors J; Herzog CE; Cuglievan B; Garcia MB
Pediatr Blood Cancer; 2024 Jun; 71(6):e30964. PubMed ID: 38514796
[No Abstract] [Full Text] [Related]
3. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial.
Marks DI; Moorman AV; Chilton L; Paietta E; Enshaie A; DeWald G; Harrison CJ; Fielding AK; Foroni L; Goldstone AH; Litzow MR; Luger SM; McMillan AK; Racevskis J; Rowe JM; Tallman MS; Wiernik P; Lazarus HM
Haematologica; 2013 Jun; 98(6):945-52. PubMed ID: 23349309
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the characteristics of primary acute myeloid leukemia with 11q23/KMT2A rearrangements in ninety patients].
Li Y; Wang Y; Wang Z; Feng L; Gao L; Shi Y; Dang H; He Q; Qin Y; Jiang Q; Jiang H; Huang X; Lai Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Dec; 40(12):1472-1477. PubMed ID: 37994126
[TBL] [Abstract][Full Text] [Related]
5. A rare KMT2A::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome.
Yu J; Song F; Zhang M; Xiao P; Feng J; Hong R; Hu Y; Huang H; Wei G
Mol Biol Rep; 2024 Apr; 51(1):561. PubMed ID: 38643442
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognosis of 28 cases of infant acute lymphoblastic leukemia].
Shi Y; Lu Y; Zhang RD; Zhang YY; Lin W; Yu JJ; Wu Y; Fan J; Qi PJ; Huang PL; Cai LX; Huang Q; Zhang P; Sun YM; Liu Y; Zheng HY
Zhonghua Er Ke Za Zhi; 2024 Jan; 62(1):49-54. PubMed ID: 38154977
[No Abstract] [Full Text] [Related]
7. Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement.
Gray ZH; Chakraborty D; Duttweiler RR; Alekbaeva GD; Murphy SE; Chetal K; Ji F; Ferman BI; Honer MA; Wang Z; Myers C; Sun R; Kaniskan HÜ; Toma MM; Bondarenko EA; Santoro JN; Miranda C; Dillingham ME; Tang R; Gozani O; Jin J; Skorski T; Duy C; Lee H; Sadreyev RI; Whetstine JR
Cell; 2023 Oct; 186(21):4528-4545.e18. PubMed ID: 37788669
[TBL] [Abstract][Full Text] [Related]
8. Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT.
Ye Y; Labopin M; Chen J; Wu D; Gedde-Dahl T; Blaise D; Socie G; Forcade E; Salmenniemi U; Maury S; Versluis J; Bazarbachi A; Nagler A; Brissot E; Li L; Luo Y; Shi J; Ciceri F; Huang H; Mohty M; Gorin NC
Blood Cancer J; 2024 May; 14(1):85. PubMed ID: 38802349
[No Abstract] [Full Text] [Related]
9. Navigating the nexus of MRD and novel agents in ALL.
Advani AS; Copelan EA
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):9-16. PubMed ID: 31808877
[TBL] [Abstract][Full Text] [Related]
10. Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
Fechina L; Popov A; Tsaur G; Henze G; Shorikov E; Makarova O; Khlebnikova O; Zhukova Y; Arakaev O; Streneva O; Verzhbitskaya T; Riger T; Solodovnikov A; Lapotentova E; Aleinikova O; Myakova N; Boichenko E; Kondratchik K; Nikonova O; Shapochnik A; Goroshkova M; Ponomareva N; Novichkova G; Karachunskiy A; Roumiantsev A
Leukemia; 2023 Nov; 37(11):2276-2281. PubMed ID: 37741948
[No Abstract] [Full Text] [Related]
11. Myeloid lineage switch in
Bataller A; Abuasab T; McCall D; Wang W; Cuglievan B; Issa GC; Jabbour E; Short N; DiNardo CD; Tang G; Garcia-Manero G; Kantarjian HM; Sasaki K
Haematologica; 2024 Jan; 109(1):293-297. PubMed ID: 37646654
[No Abstract] [Full Text] [Related]
12. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia.
Chen C; Yu W; Alikarami F; Qiu Q; Chen CH; Flournoy J; Gao P; Uzun Y; Fang L; Davenport JW; Hu Y; Zhu Q; Wang K; Libbrecht C; Felmeister A; Rozich I; Ding YY; Hunger SP; Felix CA; Wu H; Brown PA; Guest EM; Barrett DM; Bernt KM; Tan K
Blood; 2022 Apr; 139(14):2198-2211. PubMed ID: 34864916
[TBL] [Abstract][Full Text] [Related]
13.
Robinson BW; Kairalla JA; Devidas M; Carroll AJ; Harvey RC; Heerema NA; Willman CL; Ball AR; Woods EC; Ballantyne NC; Urtishak KA; Behm FG; Reaman GH; Hilden JM; Camitta BM; Winick NJ; Pullen J; Carroll WL; Hunger SP; Dreyer ZE; Felix CA
Haematologica; 2023 Oct; 108(10):2865-2871. PubMed ID: 36861410
[No Abstract] [Full Text] [Related]
14. [Clinical Analysis of Infants with Acute Lymphoblastic Leukemia (18 cases)].
Li KL; Xiong H; Li H; Wang Z; Chen Z; Yang L; Lu WJ; Qi SS; Sun M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1670-1675. PubMed ID: 38071044
[TBL] [Abstract][Full Text] [Related]
15. KMT2A amplification in B lymphoblastic leukaemia.
Wren C; Rebeiro P; Tegg E
Pathology; 2023 Aug; 55(5):738-740. PubMed ID: 36964033
[No Abstract] [Full Text] [Related]
16. Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.
Bełdzińska-Gądek K; Zarzycka E; Pastuszak K; Borman K; Lewandowski K; Zaucha JM; Prejzner W
Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38775354
[TBL] [Abstract][Full Text] [Related]
17. The MLL recombinome of acute leukemias in 2017.
Meyer C; Burmeister T; Gröger D; Tsaur G; Fechina L; Renneville A; Sutton R; Venn NC; Emerenciano M; Pombo-de-Oliveira MS; Barbieri Blunck C; Almeida Lopes B; Zuna J; Trka J; Ballerini P; Lapillonne H; De Braekeleer M; Cazzaniga G; Corral Abascal L; van der Velden VHJ; Delabesse E; Park TS; Oh SH; Silva MLM; Lund-Aho T; Juvonen V; Moore AS; Heidenreich O; Vormoor J; Zerkalenkova E; Olshanskaya Y; Bueno C; Menendez P; Teigler-Schlegel A; Zur Stadt U; Lentes J; Göhring G; Kustanovich A; Aleinikova O; Schäfer BW; Kubetzko S; Madsen HO; Gruhn B; Duarte X; Gameiro P; Lippert E; Bidet A; Cayuela JM; Clappier E; Alonso CN; Zwaan CM; van den Heuvel-Eibrink MM; Izraeli S; Trakhtenbrot L; Archer P; Hancock J; Möricke A; Alten J; Schrappe M; Stanulla M; Strehl S; Attarbaschi A; Dworzak M; Haas OA; Panzer-Grümayer R; Sedék L; Szczepański T; Caye A; Suarez L; Cavé H; Marschalek R
Leukemia; 2018 Feb; 32(2):273-284. PubMed ID: 28701730
[TBL] [Abstract][Full Text] [Related]
18. KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia.
Khater F; Lajoie M; Langlois S; Healy J; Cellot S; Richer C; Beaulieu P; St-Onge P; Saillour V; Minden M; Marzouki M; Krajinovic M; Bittencourt H; Sinnett D
Blood; 2017 Mar; 129(12):1729-1732. PubMed ID: 28069604
[No Abstract] [Full Text] [Related]
19. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.
Ribera JM; Morgades M; Montesinos P; Tormo M; Martínez-Carballeira D; González-Campos J; Gil C; Barba P; García-Boyero R; Coll R; Pedreño M; Ribera J; Mercadal S; Vives S; Novo A; Genescà E; Hernández-Rivas JM; Bergua J; Amigo ML; Vall-Llovera F; Martínez-Sánchez P; Calbacho M; García-Cadenas I; Garcia-Guiñon A; Sánchez-Sánchez MJ; Cervera M; Feliu E; Orfao A;
Cancer Med; 2020 Apr; 9(7):2317-2329. PubMed ID: 32022463
[TBL] [Abstract][Full Text] [Related]
20. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.
Forgione MO; McClure BJ; Eadie LN; Yeung DT; White DL
Cancer Lett; 2020 Jan; 469():410-418. PubMed ID: 31705930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
